Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Operating Leases (2021 - 2025)

Historic Operating Leases for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $266.0 million.

  • Rxo's Operating Leases fell 1013.51% to $266.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $266.0 million, marking a year-over-year decrease of 1013.51%. This contributed to the annual value of $266.0 million for FY2025, which is 1013.51% down from last year.
  • According to the latest figures from Q4 2025, Rxo's Operating Leases is $266.0 million, which was down 1013.51% from $202.0 million recorded in Q3 2025.
  • Rxo's Operating Leases' 5-year high stood at $296.0 million during Q4 2024, with a 5-year trough of $109.0 million in Q1 2023.
  • For the 5-year period, Rxo's Operating Leases averaged around $180.3 million, with its median value being $162.0 million (2022).
  • As far as peak fluctuations go, Rxo's Operating Leases soared by 10880.0% in 2024, and later tumbled by 2260.54% in 2025.
  • Over the past 5 years, Rxo's Operating Leases (Quarter) stood at $135.0 million in 2021, then rose by 20.0% to $162.0 million in 2022, then grew by 22.84% to $199.0 million in 2023, then soared by 48.74% to $296.0 million in 2024, then dropped by 10.14% to $266.0 million in 2025.
  • Its Operating Leases stands at $266.0 million for Q4 2025, versus $202.0 million for Q3 2025 and $201.0 million for Q2 2025.